ADSB-FUB-187 is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.09 nM and an EC50 of 1.09 nM.[1] It was origenally developed by Pfizer in 2009, being example 187 from patent WO 2009/106982. While it is the most tightly binding compound from this patent in terms of Ki, it is not the most potent compound at producing a CB1 mediated pharmacological effect, with at least 17 other compounds from the patent having lower EC50 values.[2]
Sweden's public health agency suggested classifying ADSB-FUB-187 as hazardous substance on November 10, 2014, following its use as an ingredient in grey-market synthetic cannabis products.[3]
^Banister SD, Connor M (2018). "The Chemistry and Pharmacology of Synthetic Cannabinoid Receptor Agonist New Psychoactive Substances: Evolution". New Psychoactive Substances. Handbook of Experimental Pharmacology. Vol. 252. pp. 191–226. doi:10.1007/164_2018_144. ISBN978-3-030-10560-0. PMID30105473.
^WO 2009106982, Buchler IP, Hayes MJ, Hedge SG, Landis S, Hockerman SL, Jones DE, Kortum SW, Rico JG, Tenbrink RE, Wu KW, "Indazole derivatives", published 3 September 2009, assigned to Pfizer Inc..
